Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands

Quist, Sara W.; van Schoonhoven, Alexander V.; Bakker, Stephan J. L.; Pochopień, Michał; Postma, Maarten J.; van Loon, Jeanni M. T.; Paulissen, Jeroen H. J.

doi:10.1186/s12933-023-02053-6

Cardiovascular Diabetology

Table 4 Overview of model inputs for costs within the healthcare system

From: Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands

Parameter	Value	Reference
Medication costs finerenone (per day)	€2.00 (excl. VAT)	Medicijnkosten.nl and data on file [27, 33]
Average cost of SoC (per DDD)	€2.32	Farmaocotherapeutisch Kompas [34], GIP databank [32], Data on file [27], Additional file 1
CKD 1/2 (per cycle)^a	€74	NHG guideline [5], Dutch costing manual [35] Schrauben et al. [36], NZA price index [37], Additional file 6
CKD 3 (per cycle)^a	€140	NHG guideline [5], Dutch costing manual [35] Schrauben et al. [36]., NZA price index [37], Additional file 6
CKD4^a	€301	NHG guideline [5], Dutch costing manual, Schrauben et al. [36]., NZA price index [37], Additional file 6
CKD 5 without RRT (per cycle)^a	€467	NHG guideline [5], Dutch costing manual [35] Schrauben et al. [36]., NZA price index [37], Additional file 6
Haemodialysis and peritoneal dialysis (per cycle)	€39,179	Mohnen et al. [28]
Acute kidney transplant (one cycle)	€24,523	Mohnen et al. [28]
Post-acute kidney transplant (per cycle)	€6449	Mohnen et al. [28]
Acute MI (one cycle)	€4038	Van Schoonhoven et al. [29]
Post-acute MI (post-acute) (per cycle)	€748	Van Schoonhoven et al. [29]
Acute IS and ICH stroke (one cycle)	€11,169	Van Schoonhoven et al. [29]
Post-acute IS and ICH stroke (per cycle)	€3157	Van Schoonhoven et al. [29]
Acute hospitalisation for heart failure (one cycle)	€2578	Van Schoonhoven et al. [29]
Post-acute hospitalization for heart failure (per cycle)	€274	Van Schoonhoven et al. [29]
Subsequent CV event (per event)	€4852	Van Schoonhoven et al. [29]
Hyperkalemia (not leading to hospitalization) (one cycle)^b	€306	GIP databank [32], assumption: weighted average of calcium polystyrene sulfonate, sodium polystyrene sulfonate, sodium zirconium cyclosilicate, or patiromer
Hyperkalemia (leading to hospitalization) (one cycle)^c	€2873	Dutch costing manual [35], DBC for dialysis: 140301010 assumption
Atrial fibrillation/atrial flutter (one cycle)	€1160	Ringborg et al. [31]

CBS Central Agency for Statistics, CKD chronic kidney disease, CV cardiovascular, DDD daily defined dose, eGFR estimated glomerular filtration rate, GP general practitioner, ICH intracerebral haemorrhage, IS ischaemic stroke, MI myocardial infarction, NHG Dutch Society of Internal Medicine, RRT renal replacement therapy, SoC standard of care, VAT value added tax
^aResource used per CKD health state included visits to the GP, outpatient visits, eGFR and albuminuria assessments, treatment with an ACE inhibitor, an influenza vaccine, and risk for a hospital admission unrelated to CV outcomes
^bPatients experiencing hyperkalaemia without hospitalization were assumed to use calcium polystyrene sulfonate, sodium polystyrene sulfonate, calcium polystyrene sulfonate, sodium zirconium cyclosilicate, patiromer
^cPatients experiencing hyperkalaemia with hospitalization were in 80% of the cases assumed to have been admitted to hospital for 3 days. In 20% of cases the patients were admitted to an intensive care unit for one day and experienced regular hospital admission for 2 days. 10% of patients experienced acute dialysis

Back to article page

ISSN: 1475-2840

Contact us

Submission enquiries: journalsubmissions@springernature.com